Literature DB >> 23650051

Role of Nrf2 in cancer photodynamic therapy: regulation of human ABC transporter ABCG2.

Toshihisa Ishikawa1, Yoshinaga Kajimoto, Wei Sun, Hiroshi Nakagawa, Yutaka Inoue, Yoji Ikegami, Shin-Ichi Miyatake, Toshihiko Kuroiwa.   

Abstract

Photodynamic therapy (PDT) is a recently developed anticancer treatment that utilizes the generation of singlet oxygen and other reactive oxygen species in cancer tissue. In response to oxidative stress, NF-E2-related transcription factor (Nrf2) encoded by the NFE2L2 gene plays a key role in transcriptional upregulation of many target genes, including those for metabolizing enzymes and transporters essential for cellular defense. Recent studies have provided evidence that Nrf2 regulates the transcription of the human ABC transporter ABCG2 gene, which is critically involved in the cellular accumulation of porphyrins in PDT. Nrf2 interacts with the antioxidant responsive element (ARE) located in the promoter region of human ABCG2 gene. Nrf2-specific siRNA treatments suppressed the induction of ABCG2 expression after the photoactivation of porphyrins in vitro. One SNP (-617C>A; rs6721961) in the ARE-like loci of the human Nrf2 gene is considered to affect the positive feedback loop of transcriptional activation of the Nrf2 gene as well as its target genes including ABCG2. Since patients have demonstrated individual differences in their response to PDT, Nrf2-mediated transcriptional activation of the ABCG2 gene in cancer may affect patients' responses to PDT as well as chemotherapy.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  ABC transporters; Nrf2; aminolevulinic acid (ALA); cancer; gefitinib; mRNA; metabolism; oxidative stress; porphyrin; single nucleotide polymorphism (SNP)

Mesh:

Substances:

Year:  2013        PMID: 23650051     DOI: 10.1002/jps.23563

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

Review 1.  Recent advances in sonodynamic immunotherapy.

Authors:  Hui Wang; Guo-Qing Sui; Zhi-Xia Sun; Jia-Rui Du; Yang Wang; Zong-Hua Yue; Han-Yu Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-13       Impact factor: 4.322

2.  Poor man's fluorescence?

Authors:  Walter Stummer
Journal:  Acta Neurochir (Wien)       Date:  2015-06-19       Impact factor: 2.216

3.  ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity.

Authors:  Charlotte Gauthier; Csilla Ozvegy-Laczka; Gergely Szakacs; Balazs Sarkadi; Attilio Di Pietro
Journal:  Front Pharmacol       Date:  2013-11-07       Impact factor: 5.810

4.  Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis.

Authors:  Gladys O Latunde-Dada; Abas H Laftah; Patarabutr Masaratana; Andrew T McKie; Robert J Simpson
Journal:  Front Pharmacol       Date:  2014-06-04       Impact factor: 5.810

5.  The Cisplatin-Derived Increase of Mitochondrial Reactive Oxygen Species Enhances the Effectiveness of Photodynamic Therapy via Transporter Regulation.

Authors:  Hiromi Kurokawa; Hiromu Ito; Hirofumi Matsui
Journal:  Cells       Date:  2019-08-17       Impact factor: 6.600

6.  Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer.

Authors:  Guoyun Wan; Xuheng Chen; Haijiao Wang; Shenglei Hou; Qian Wang; Yuanyuan Cheng; Qian Chen; Yingge Lv; Hongli Chen; Qiqing Zhang
Journal:  J Nanobiotechnology       Date:  2021-10-29       Impact factor: 10.435

7.  Natural Compounds Modulate Drug Transporter Mediated Oral Cancer Treatment.

Authors:  Hsiang Yang; Yu-Ching Wei; Wan-Chun Li; Hsin-Yung Chen; Hung-Ying Lin; Chun-Pin Chiang; Hsin-Ming Chen
Journal:  Biomolecules       Date:  2020-09-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.